Comparative Pharmacology
Head-to-head clinical analysis: ALYQ versus SELARSDI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALYQ versus SELARSDI.
ALYQ vs SELARSDI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALYQ (alectinib) is a selective and potent anaplastic lymphoma kinase (ALK) inhibitor. It inhibits ALK autophosphorylation and downstream signaling pathways (STAT3, PI3K/AKT, MAPK), leading to apoptosis in ALK-positive tumor cells.
Selective angiotensin II type 1 receptor antagonist that blocks vasoconstriction and aldosterone secretion.
Intravenous: 400 mg on Day 1, then 200 mg daily for 4 days; total 5 doses per cycle.
Intravenous 0.15 mg/kg every 8 hours for 14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours in adults with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is approximately 11 hours (range 7–15 hours), supporting twice-daily dosing; half-life may be prolonged in renal impairment.
Primarily renal excretion as unchanged drug (approximately 70-80%) and biliary/fecal elimination (20-30%) following intravenous administration.
Primarily renal excretion of unchanged drug (approximately 70%) and glucuronide conjugate (approximately 20%); biliary/fecal elimination accounts for less than 10%.
Category C
Category C
Unknown
Unknown